ANI Pharmaceuticals: 76% YoY growth in Purified Cortrophin Gel net revenues, $1.06-$1.12 bln FY26 revenue.

• ANI Pharmaceuticals reports strong growth in 2025 • Rare Disease business up 76% YoY • Purified Cortrophin Gel net revenues $347.8 million • ILUVIEN and YUTIQ net revenues $74.9 million • 2026 financial guidance: + Total net revenues $1,055 million to $1,115 million + Cortrophin Gel net revenues $540 million to $575 million + Adjusted non-GAAP EBITDA $275 million to $290 million